Asimov Press The Quest for Oral GLP-1s
Mar 16, 2026
A deep dive into why oral GLP-1 pills are hard to make and why patients prefer them over injections. The science of peptide degradation and clever molecular tweaks that extended drug half life. How oral semaglutide uses a co‑formulation to sneak past the stomach. Radical ideas like edible microbes and spirulina as low‑cost peptide factories. Regulatory and cost hurdles for making oral GLP‑1s widely available.
AI Snips
Chapters
Transcript
Episode notes
Gila Monster Led To First Long‑Lasting GLP-1 Drug
- John Eng noticed the Gila monster's prolonged glucose stability and isolated exendin-4, a peptide resistant to DPP-4.
- Exendin-4 inspired Exenatide, the first twice-daily injectable GLP-1 receptor agonist approved in 2005.
GLP-1s Shifted From Diabetes To Obesity And Cardio Benefits
- GLP-1 receptor agonists, initially for diabetes, caused significant weight loss and cardiovascular benefits, driving a sharp prescription rise.
- Semaglutide trials showed up to ~15% weight loss and reduced major cardiovascular events in large studies.
Why Oral Peptides Rarely Survive The Gut
- Oral peptide drugs face stomach acid and peptidases that break amino acid bonds, so most are digested as food.
- Even surviving peptides are rapidly degraded by DPP-4 in blood and excreted by kidneys without engineering.